GlassScriptPhysician profile
Julia Murray Teubert
NPI 1396123170
$2,720.21
in general payments reported to CMS, 2019-2025
21 companies · $1,159 in 2025
The $1,159 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.29 · 2022: $94.21 · 2023: $434 · 2024: $1,018 · 2025: $1,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,611.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $724.13 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Shield Therapeutics INC | $301.38 | 2024 | |
| Amgen INC. | $267.33 | 2023-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $245.93 | 2023-2025 | Veozah |
| Abbvie INC. | $226.95 | 2023-2025 | |
| Exact Sciences Corporation | $226.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $140.86 | 2022-2024 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.43 | 2023-2025 | Xifaxan |
| Pfizer INC. | $108.03 | 2023-2025 | |
| Esperion Therapeutics, INC. | $72.19 | 2024-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $60.63 | 2023-2025 | |
| Glaxosmithkline, LLC. | $48.83 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Dexcom, INC. | $39.90 | 2023-2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $23.68 | 2025 | Rexulti |
| Eisai INC. | $21.98 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $19.23 | 2023 | Intellis Adaptivestim |
| Verona Pharma, INC. | $18.27 | 2025 | Ohtuvayre |
| Insulet Corporation | $14.32 | 2024 | Omnipod |
| Actelion Pharmaceuticals US, INC. | $14.29 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.95 | 2023 | |
| Phathom Pharmaceuticals, INC. | $10.90 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Teubert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.